Palvella Therapeutics (PVLA) Set to Announce Quarterly Earnings

Palvella Therapeutics (NASDAQ:PVLA) is scheduled to release its quarterly earnings data before the market opens on Monday, March 31. Analysts are predicting that the company will report earnings of ($0.39) per share for the quarter.

Palvella Therapeutics Shares Rise

During trading on Monday, Palvella Therapeutics saw its stock increase by $0.26, bringing the price to $28.40. A total of 23,005 shares were traded, which is below the average volume of 61,238. The company's 50-day moving average stands at $18.78. Palvella Therapeutics has experienced a fifty-two week low of $6.20 and a high of $29.27. Currently, the firm maintains a market capitalization of $318.68 million, a PE ratio of -2.35, and a beta of 0.54.

Insights from Wall Street Analysts

Palvella Therapeutics has drawn attention from various research analysts. TD Cowen began coverage of the stock and gave it a "buy" rating with a target price of $44.00. Similarly, Cantor Fitzgerald also initiated coverage with an "overweight" rating. HC Wainwright reaffirmed a "buy" rating with a target price of $38.00, and Scotiabank initiated coverage with a "sector outperform" rating and a target price of $50.00. Furthermore, Canaccord Genuity reaffirmed a "buy" rating with a $39.00 target price. Overall, five research analysts have rated the stock positively, with a consensus rating of "Buy" and an average target price of $42.75 according to MarketBeat.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for individuals suffering from serious, rare genetic skin conditions. The company, formerly known as Pieris Pharmaceuticals Inc, is headquartered in Wayne, Pennsylvania.

Investment Considerations

Before deciding to invest in Palvella Therapeutics, it is essential to consider recent market insights. While the company currently holds a Buy rating from analysts, there are other stocks that some experts believe may offer better investment opportunities. As always, conducting thorough research is vital before making any investment decisions.

Palvella, Earnings, Stock